This study is not yet accepting patients

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

a study on Melanoma Skin Cancer/Melanoma Head and Neck Cancer Solid Tumor

Summary

for people ages 18 years and up (full criteria)
at La Jolla, California
study started
estimated completion
Gregory Daniels, MD, PhDEzra Cohen, MD

Description

Summary

To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is suppressed from attacking these special tumor fighting cells. This is called transfer of autologous (they came from you) tumor infiltrating lymphocytes (the cells that have been grown in the laboratory. Participants getting these cell infusions will also be treated with interleukin-2 (IL-2).

Official Title

Phase I Trial of Lymphodepletion Followed by Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Keywords

Metastatic Melanoma Locally Advanced Refractory/Recurrent Melanoma Metastatic Head and Neck Cancer Locally Advanced Refractory/Recurrent Head and Neck Cancer melanoma metastatic head and neck cancer solid tumor adoptive cell therapy autologous IL-2 Head and Neck Neoplasms Interleukin-2 Autologous Tumor Infiltrating Lymphocytes High-Dose Interleukin 2

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patients with a histologically confirmed diagnosis of head and neck squamous cell carcinoma OR metastatic cutaneous or mucosal melanoma measurable per RECIST.
  • Progressive squamous cell cancer of the head and neck or metastatic melanoma since prior systemic treatment and who are:
  • Not candidates for known curative intent therapy.
  • Progressed following at least one prior systemic therapy.
  • Have advanced melanoma unresectable stage III or stage IV
  • Have advanced head and neck recurrent or metastatic disease
  • Have no more than 3 brain metastases. Note: If lesions are symptomatic or ≥ 1 cm each, these lesions must have been treated and stable for 3 months for the patient to be eligible.
  • Life expectancy of greater than 3 months.
  • ECOG Performance Status of 0 or 1.
  • Adequate organ and marrow function
  • Seronegative for HIV antibody.
  • Seronegative for Hepatitis B antigen, or Hepatitis C antibody or antigen.
  • More than four weeks has elapsed since the patient received any prior systemic therapy at the time of enrollment.
  • Patient has stable or progressing disease after at least one prior treatment.
  • Six weeks or more have elapsed since the patient received any prior anti-CTLA4 antibody therapy

You CAN'T join if...

  • Currently using investigational agents.
  • Had prior cell transfer therapy which included a non-myeloablative or myeloablative chemotherapy regimen.
  • Patient is a female of child-bearing potential who is pregnant or breastfeeding
  • Patient requires immune suppressive therapy including but not limited to greater than physiologic steroid replacement.
  • Active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.
  • Patient has any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS).
  • Patient has opportunistic infections.
  • Patient has a history of coronary revascularization or ischemic symptoms.
  • Patients with clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block.

Location

  • UC San Diego Moores Cancer Center not yet accepting patients
    La Jolla California 92093 United States

Lead Scientists

  • Gregory Daniels, MD, PhD
    Dr. Daniels coordinates our clinical program in melanoma. His own research involves understanding the link between autoimmunity and tumor immunity in developing more effective and less toxic vaccines and immune stimulatory approaches for patients with melanoma.
  • Ezra Cohen, MD
    Professor, Medicine. Authored (or co-authored) 172 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Gregory Daniels
ID
NCT03991741
Phase
Phase 1
Study Type
Interventional
Last Updated